Healthcare Industry News:  computed tomography 

Devices Radiology Oncology

 News Release - April 18, 2007

Imaging Diagnostic Systems' Director of Clinical Research Cautions Against Excess Radiation Dose to Breasts

Contributes Chapter to Upcoming Lung and Breast Cancer Imaging Publication

FORT LAUDERDALE, Fla., April 18 (HSMN NewsFeed) -- Imaging Diagnostic Systems, Inc., (OTC Bulletin Board: IMDS ) a pioneer in laser optical breast imaging systems, announced that Professor Eric Milne, M.D., IDSI Director of Clinical Research, has contributed to a comprehensive new book, "Cancer Imaging: Lung and Breast Carcinomas," edited by Professor M.A. Hayat.

Professor Milne's chapter, "Breast Dose in Thoracic computed tomography," examines the risks of inducing breast cancer as a result of the ionizing radiation received during CT exams of the thorax and upper abdomen. Citing results stemming from his original 1992 study, which demonstrated that large doses of ionizing radiation, equivalent to the dose from 15 to 60 mammograms, are absorbed by the female breast as a result of each chest CT exam, Milne suggests that referring physicians should carefully weigh the clinical necessity for thoracic scans in female and pediatric patients and cautions against the use of CT scans as a screening procedure for lung cancer, coronary artery calcification, or pediatric lung disease.

"The number of CT scans performed per year, for every 1,000 persons, has increased enormously in the USA over the last five years," Milne explains. "We now hold the world record at 172.5 scans for every group of 1,000 people. A conservative estimate of the carcinogenic effects of this massive irradiation would indicate an increase of 16,000 breast cancers."

Commented Tim Hansen, IDSI President and CEO: "We believe that imaging the angiogenesis process using lasers not only presents new information to the diagnostician, but also avoids adding to the patient's cumulative carcinogenic radiation dose. As Dr. Milne notes, physicians should be aware of the dose consequences and examine alternatives that are available."

The book, which will be published by Elsevier, is currently in press.

About Imaging Diagnostic Systems, Inc.

Imaging Diagnostic Systems, Inc. has developed a revolutionary new imaging device to aid in the detection and management of breast cancer. The CTLM® system is a breast imaging system that utilizes patented continuous wave laser technology and computer algorithms to create 3-D images of the breast. The procedure is non-invasive, painless, and does not expose the patient to ionizing radiation or painful breast compression. CT Laser Mammography (CTLM®) is designed to be used in conjunction with mammography. It reveals information about blood distribution in the breast and may visualize the process of angiogenesis, which usually accompanies tumor growth.

Imaging Diagnostic Systems is currently collecting data from clinical sites for the future filing of an FDA Premarket Approval (PMA) for the computed tomography Laser Mammography (CTLM®) system to be used as an adjunct to mammography. The FDA has determined that the Company's clinical study is a non-significant risk (NSR) investigational device study under 812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR 812). The CTLM system is limited by United States Federal Law to investigational use only in the United States. The CTLM system has received other registrations including CE, CMDCAS Canadian License, China SFDA, UL, ISO 9001:2000, ISO 13485:2003 and FDA export certification.

For more information, visit our corporate website: www.imds.com

As contemplated by the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future, anticipated, or projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates or predictions of future results or events and there can be no assurance that actual results or events will not materially differ from expectations. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company's filings with the Securities and Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements.


Source: Imaging Diagnostic Systems

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps 2 - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps 2 - available on the Apple App Store for iPhone and iPad.